These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33765606)

  • 1. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.
    Zhang Z; Xing X; Guan P; Song S; You G; Xia C; Liu T
    Eur J Med Chem; 2021 May; 217():113314. PubMed ID: 33765606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
    Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
    Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).
    Bian S; Zhang R; Nie J; Zhu M; Xie Z; Liao C; Wang Q
    Expert Opin Ther Pat; 2024 Sep; 34(9):789-806. PubMed ID: 38994687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing polo-like kinase 1 inhibitors.
    Huang X; Xie Z; Liao C
    Future Med Chem; 2020 May; 12(10):869-871. PubMed ID: 32233804
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.
    Jadhav M; Sankhe K; Bhandare RR; Edis Z; Bloukh SH; Khan TA
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putative Anti-Cancer Drug Candidate Targeting the 'PLK-1-Polo-Box Domain' by High Throughput Virtual Screening: A Computational Drug Design Study.
    Shakil S; Abuzinadah MF
    Crit Rev Eukaryot Gene Expr; 2019; 29(3):251-261. PubMed ID: 31679235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinases inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
    Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.
    Qi B; Zhong L; He J; Zhang H; Li F; Wang T; Zou J; Lin YX; Zhang C; Guo X; Li R; Shi J
    J Med Chem; 2019 Sep; 62(17):7697-7707. PubMed ID: 31381325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
    Lee KS; Burke TR; Park JE; Bang JK; Lee E
    Trends Pharmacol Sci; 2015 Dec; 36(12):858-877. PubMed ID: 26478211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
    Tsykunova G; Reikvam H; Ahmed AB; Nepstad I; Gjertsen BT; Bruserud Ø
    Expert Opin Investig Drugs; 2012 May; 21(5):587-603. PubMed ID: 22424119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
    Jayanthan A; Hofmann B; Meier-Stephenson V; Perinpanayagam M; Dunn SE; Boklan J; Trippett TM; Truong TH; Narendran A
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):e359-e370. PubMed ID: 30702467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
    Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P
    Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLK1 as an oncology target: current status and future potential.
    McInnes C; Wyatt MD
    Drug Discov Today; 2011 Jul; 16(13-14):619-25. PubMed ID: 21601650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.